Welcome and thank you for visiting our website. To help acquaint you with our company, I’d like to tell you a little bit about who we are and what we are trying to accomplish as an organization.

My name is David Geliebter. I founded Critical Diagnostics in 2004, not long after my father Jack died of heart failure. I watched the disease slowly, yet progressively, rob this once vibrant man first of his strength and then his will to live. Frequent visits to the emergency room, an onslaught of medications and other interventions, plus constant hospital readmissions, eventually took their toll.

At the time, the standard of care in helping diagnose heart failure, in addition to clinical observations, included the use of BNP or NT-proBNP. That’s still the case today. But while BNP or NT-proBNP have an established role in diagnosis, there is still a need for additional clinical tools to aid in improving outcomes for chronic heart failure patients.

Now, after eight years and millions of dollars in research and development, after more than 50 human clinical studies involving tens of thousands of patients, after over 100 published peer-reviewed articles and posters, there’s a new commercially available cardiac biomarker to help you fill the gap in the management of your heart failure patients. It’s called ST2, and it’s available only from Critical Diagnostics.

In study after study, ST2 has consistently demonstrated that it is an independent and powerful predictor of risk—and when used in conjunction with BNP or NT-proBNP, ST2 provides complimentary information.

ST2 levels change rapidly in response to changes in the patient’s condition—sometimes within hours—thus helping you to focus on those requiring immediate medical attention.

It’s also important to note that ST2 levels are not adversely affected by such factors as age, gender, BMI, atrial fibrillation, smoking history of heart failure, anemia, and impaired renal function.

And finally, ST2 has a single cutpoint, removing any guesswork, making clinical decisions easier.

We are committed, passionate and excited about changing the practice of medicine by helping physicians to better assess and treat their heart failure patients, in turn improving patient outcomes and the quality of life for all heart failure patients, while, in the process, reducing healthcare costs.

Thanks again for spending time learning more about Critical Diagnostics and ST2.

Gratefully,



David Martin Geliebter
CEO
dgeliebter@criticaldiagnostics.com

30-day rehospitalization
White Paper

To view a copy, please click here